March 20, 2024
2 min watch
Save
VIDEO: Notable PFS improvement from nivolumab plus ipilimumab for colorectal cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Afsaneh Barzi, MD, PhD, discusses the results of the CheckMate 8HW study.
The study, presented at ASCO Gastrointestinal Cancers Symposium, found that nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) significantly improved PFS compared with chemotherapy in previously untreated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
"In this study, the PFS at 2 years was 72%, so it was a significant improvement in PFS in this patient population at 2 years, which hopefully would translate to overall survival benefit," Barzi, a medical oncologist at City of Hope, said.
Reference:
- Andre T, et al. Abstract LBA768. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Barzi reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.